On the stock market since 2026, it operates in the world of health and science. It has 511 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Business Quality: Profit power and business quality trail similar companies in the sector.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades 19% below its peak. The market has trimmed its expectations for the company.
Sales run at $18.6M a year. A small number, but proof the product has real buyers.
There is $270M in the vault; even if every debt were paid off, $266.3M would remain.
The average analyst price target is $25.00 — 85% above today’s price.
A loss of $76.7M against $18.6M in annual sales.
Over the last 12 months, executives reported 18 sells against just 0 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, RNA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: RNA is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (23/100) says the stock isn’t cheap.